Trial Profile
A Phase Ib, Open-Label, Sequential, Dose-Finding, Study of AMG 706 [motesanib] in Combination With Gemcitabine to Treat Subjects With Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2007
Price :
$35
*
At a glance
- Drugs Motesanib (Primary) ; Gemcitabine
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 29 Oct 2006 New trial record.